secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2024-04-09T23:59:59+00:00
Accession:  0001193125-24-090983
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies appoints Kyle Piskel as CFO effective April 8, 2024
----------------------------------------------------------------------------

- Kyle Piskel promoted from Principal Accounting Officer to CFO; reports to CEO Chad Robins.
- Base salary set at $380,000 per year; target bonus of 40% of eligible earnings.
- Receives RSU grant of 31,260 shares (4-year vesting) and PSU grant of 75,000 shares (3-year performance period).
- Also entitled to annual equity refresh of 43,740 RSUs, bringing 2024 total equity grants to 150,000 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312524090983/0001193125-24-090983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312524090983/d814314d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-090983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer